Our initial humanized liver mouse model (hu-PIRF) has now been fully validated in-house thanks to our collaboration with Professor Karl-Dimiter Bissig of Duke University and has been tested by early adopters in Europe since 2020 year-end. We look forward to introducing this hu-liver disease model. Feel free to contact us if you have some revolutionary ideas on using a 100% human/0% mouse hepatocyte driven disease model for NASH, HBV, HCV, PK/PD, drug metabolism, or hepatotoxicity.
The market for humanized liver models is expected to reach 23 million dollars (U.S.) by 2026.
TransCure release a brand new in vivo pharmacology hu-liver model. Only pure human liver cells engrafted in a mouse liver without any murine hepatocites activity contamination. Best in class!
Contact our team of experts for a preliminary discussion to organize your experiment and work together on a tailor-made protocol.